Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02649959 · ClinicalTrials.gov registry record · Phase 3
An Open Label Study of CM-AT for the Treatment of Children With Autism
A Phase 3 study of Autism, sponsored by Curemark.
- Active
- Registry status
- Phase 3
- Development phase
- 405
- Enrollment target
- 20
- Study locations
NCT02649959 is a Phase 3 study of Autism that is active but no longer recruiting, run by Curemark. The registered enrollment target is 405 participants, above the 180-participant average among 104 other Autism trials with a reported enrollment target (125% higher). The trial reports 20 study locations across 12 states.
The verdict
NCT02649959, a Phase 3 study of Autism, is active but no longer recruiting, sponsored by Curemark.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 405 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase III, open label extension study evaluating the continued safety and efficacy of CM-AT in pediatric patients with autism with all levels of fecal chymotrypsin.
Conditions Studied
Interventions
- DRUG CM-AT
Study Locations (20)
California
- N.R.C. Research Institute - Orange
- M.I.N.D. Institute (Univ.of California, Davis) - Sacramento
- University of California (U.C.S.F.) - San Francisco
Florida
- Segal Institute For Clinical Research - North Miami
- Advent Health -Lake Mary Pediatrics - Orange City
- A.P.G. Research - Orlando
New Jersey
- Children'S Specialized Hospital - Egg Harbor
- Children's Specialized Hospital - Toms River
- Clinical Research Center of Nj - Voorhees Township
Arizona
- Southwest Autism Research & Resource Center (S.A.R.R.C.) - Phoenix
- University of Arizona, Pediatrics Multidisciplinary Research Unit - Tucson
Louisiana
- Lake Charles Clinical Trials - Lake Charles
- L.S.U. Health Sciences Center - Shreveport
Arkansas
- Arkansas Children'S Hosp. Research Institute (A.C.H.R.I.) - Little Rock
Colorado
- IMMUNOe Research Centers - Centennial
Connecticut
- Yale Child Study Center - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 405 participants |
| Start Date | 2015-10 |
| Est. Completion | 2028-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02649959
The ClinicalTrials.gov registry entry for NCT02649959 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 405 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 180-participant average among 104 other Autism trials with a reported enrollment target (125% higher). The listed sponsor is Curemark, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Autism appearing as the primary indexed condition, and to 1 intervention - of which CM-AT is the first listed.
NCT02649959 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, Florida, New Jersey.
Frequently Asked Questions
What is clinical trial NCT02649959 about?
NCT02649959 is a clinical study titled "An Open Label Study of CM-AT for the Treatment of Children With Autism". This is a Phase III, open label extension study evaluating the continued safety and efficacy of CM-AT in pediatric patients with autism with all levels of fecal chymotrypsin.
What is the current status of trial NCT02649959?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 405 participants. The study started on 2015-10. Estimated completion is 2028-01.
What conditions does trial NCT02649959 study?
This clinical trial studies the following conditions: Autism.
What interventions are being tested in trial NCT02649959?
The interventions under investigation include: CM-AT (DRUG).
Who is sponsoring clinical trial NCT02649959?
This trial is sponsored by Curemark, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02649959 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Autism
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Pediatric Open-Label Extension Study
COMPLETED · Phase 3
-
Study of Paliperidone ER in Adolescents and Young Adults With Autism
COMPLETED · Phase 3
-
A Pilot Study of Daytrana TM in Children With Autism Co-Morbid for Attention Deficit Hyperactivity Disorder (ADHD) Symptoms
COMPLETED · Phase 3
-
A Trial of CM-AT in Children With Autism
COMPLETED · Phase 3
-
COMPASS Across Settings (CAST) for Improving Transition Outcomes for Students With ASD
RECRUITING · NA
-
Online Pivotal Response Treatment Training in Autism Spectrum Disorder
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.